What is HC Wainwright’s Estimate for TARS Q1 Earnings?

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) – Investment analysts at HC Wainwright cut their Q1 2026 earnings per share estimates for shares of Tarsus Pharmaceuticals in a research note issued on Tuesday, February 24th. HC Wainwright analyst M. Caufield now expects that the company will earn ($0.42) per share for the quarter, down from their prior estimate of $0.05. The consensus estimate for Tarsus Pharmaceuticals’ current full-year earnings is ($3.17) per share. HC Wainwright also issued estimates for Tarsus Pharmaceuticals’ Q2 2026 earnings at ($0.17) EPS, Q3 2026 earnings at ($0.07) EPS, Q4 2026 earnings at $0.09 EPS, FY2026 earnings at ($0.56) EPS, FY2027 earnings at $2.33 EPS, FY2028 earnings at $3.10 EPS and FY2029 earnings at $4.68 EPS.

Tarsus Pharmaceuticals (NASDAQ:TARS) last posted its quarterly earnings results on Monday, February 23rd. The company reported ($0.20) EPS for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.01). Tarsus Pharmaceuticals had a negative net margin of 14.72% and a negative return on equity of 19.63%. The company had revenue of $151.67 million during the quarter, compared to analyst estimates of $144.56 million.

Several other analysts have also issued reports on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Tarsus Pharmaceuticals in a research report on Thursday, January 22nd. Oppenheimer upped their target price on Tarsus Pharmaceuticals from $95.00 to $105.00 and gave the stock an “outperform” rating in a research note on Wednesday. Guggenheim lifted their price target on Tarsus Pharmaceuticals from $87.00 to $90.00 and gave the company a “buy” rating in a research note on Wednesday. Wall Street Zen upgraded Tarsus Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday, November 8th. Finally, The Goldman Sachs Group reaffirmed a “neutral” rating and issued a $68.00 price objective on shares of Tarsus Pharmaceuticals in a research note on Thursday, February 5th. Two analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $87.00.

Tarsus Pharmaceuticals Price Performance

TARS stock opened at $75.87 on Thursday. The company’s 50-day moving average price is $72.12 and its two-hundred day moving average price is $68.43. The firm has a market cap of $3.23 billion, a P/E ratio of -46.83, a P/E/G ratio of 1.05 and a beta of 0.57. The company has a quick ratio of 4.25, a current ratio of 3.85 and a debt-to-equity ratio of 0.21. Tarsus Pharmaceuticals has a 12 month low of $38.51 and a 12 month high of $85.25.

Insider Buying and Selling at Tarsus Pharmaceuticals

In other news, CEO Bobak R. Azamian sold 6,000 shares of the business’s stock in a transaction dated Wednesday, December 24th. The stock was sold at an average price of $82.51, for a total transaction of $495,060.00. Following the sale, the chief executive officer directly owned 857,991 shares in the company, valued at approximately $70,792,837.41. The trade was a 0.69% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Dianne C. Whitfield sold 7,397 shares of the company’s stock in a transaction that occurred on Tuesday, December 16th. The shares were sold at an average price of $80.10, for a total value of $592,499.70. Following the completion of the transaction, the insider directly owned 38,958 shares of the company’s stock, valued at $3,120,535.80. This represents a 15.96% decrease in their position. The SEC filing for this sale provides additional information. Company insiders own 8.97% of the company’s stock.

Institutional Investors Weigh In On Tarsus Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in TARS. Deep Track Capital LP increased its position in Tarsus Pharmaceuticals by 71.4% in the 3rd quarter. Deep Track Capital LP now owns 3,000,000 shares of the company’s stock valued at $178,290,000 after acquiring an additional 1,250,000 shares during the period. Janus Henderson Group PLC grew its stake in shares of Tarsus Pharmaceuticals by 34.1% in the fourth quarter. Janus Henderson Group PLC now owns 1,930,325 shares of the company’s stock worth $158,062,000 after purchasing an additional 491,326 shares during the last quarter. Norges Bank acquired a new stake in Tarsus Pharmaceuticals in the second quarter valued at $19,095,000. M&T Bank Corp increased its holdings in Tarsus Pharmaceuticals by 11,730.0% in the fourth quarter. M&T Bank Corp now owns 437,119 shares of the company’s stock valued at $35,791,000 after purchasing an additional 433,424 shares during the period. Finally, MPM Bioimpact LLC bought a new position in Tarsus Pharmaceuticals during the 2nd quarter worth $13,834,000. 90.01% of the stock is currently owned by institutional investors and hedge funds.

More Tarsus Pharmaceuticals News

Here are the key news stories impacting Tarsus Pharmaceuticals this week:

• Positive Sentiment: Oppenheimer raised its price target materially and reiterated a positive stance (Outperform), which supports upside expectations for the shares. Oppenheimer Raises PT
• Positive Sentiment: Guggenheim raised its price target on TARS to $90 and maintained a Buy rating, providing additional analyst-level backing for further gains. Guggenheim PT $90
• Positive Sentiment: Tarsus announced management will participate in upcoming investor conferences—this increases management access to investors and can help sustain the re-rating momentum if management delivers encouraging updates. Investor Conferences
• Neutral Sentiment: A market commentary questioned whether Tarsus has been re-rated too cautiously following XDEMVY adoption headlines; this article frames debate about valuation vs execution but does not add hard fundamentals. Market Rerate Analysis
• Negative Sentiment: HC Wainwright trimmed multiple near-term and multi-year EPS forecasts in its Feb. 24 research note — lowering Q1 2026 to about ($0.42) (from $0.05), Q2 to ~($0.17) (from $0.09), Q3 to ~($0.07) (from $0.18), and cutting Q4/QFY and FY2027–FY2029 targets (e.g., FY2027 to $2.33 from $2.90, FY2028 to $3.10 from $4.26, FY2029 to $4.68 from $5.87). These downward revisions increase short-term earnings uncertainty and weigh on fundamental expectations.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company’s research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus’s lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.